JP2017529365A - 大環状ｌｒｒｋ２キナーゼ阻害剤 - Google Patents

大環状ｌｒｒｋ２キナーゼ阻害剤 Download PDF

Info

Publication number
JP2017529365A
JP2017529365A JP2017515823A JP2017515823A JP2017529365A JP 2017529365 A JP2017529365 A JP 2017529365A JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017529365 A JP2017529365 A JP 2017529365A
Authority
JP
Japan
Prior art keywords
alkyl
het
halo
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529365A5 (enExample
Inventor
ホフラック，ジャン
ブロム，ペトラ
ラヴェルニュ，オリヴィエ
ゴメス，シルヴィー
Original Assignee
オンコデザイン エス．ア．
オンコデザイン エス．ア．
イプセン ファーマ エス．ア．エス
イプセン ファーマ エス．ア．エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコデザイン エス．ア．, オンコデザイン エス．ア．, イプセン ファーマ エス．ア．エス, イプセン ファーマ エス．ア．エス filed Critical オンコデザイン エス．ア．
Publication of JP2017529365A publication Critical patent/JP2017529365A/ja
Publication of JP2017529365A5 publication Critical patent/JP2017529365A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017515823A 2014-09-17 2015-09-17 大環状ｌｒｒｋ２キナーゼ阻害剤 Pending JP2017529365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14290279.0 2014-09-17
EP14290279 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017529365A true JP2017529365A (ja) 2017-10-05
JP2017529365A5 JP2017529365A5 (enExample) 2018-09-13

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515823A Pending JP2017529365A (ja) 2014-09-17 2015-09-17 大環状ｌｒｒｋ２キナーゼ阻害剤

Country Status (20)

Country Link
US (1) US10377772B2 (enExample)
EP (1) EP3194405B1 (enExample)
JP (1) JP2017529365A (enExample)
KR (1) KR20170048599A (enExample)
CN (1) CN107108641A (enExample)
AU (1) AU2015316801B2 (enExample)
BR (1) BR112017005299A2 (enExample)
CA (1) CA2960777A1 (enExample)
DK (1) DK3194405T3 (enExample)
EA (1) EA032838B1 (enExample)
ES (1) ES2717510T3 (enExample)
HU (1) HUE043972T2 (enExample)
IL (1) IL251054B (enExample)
MX (1) MX2017003470A (enExample)
PL (1) PL3194405T4 (enExample)
SG (1) SG11201701936WA (enExample)
TR (1) TR201904514T4 (enExample)
TW (1) TW201625639A (enExample)
WO (1) WO2016042089A1 (enExample)
ZA (1) ZA201701841B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516551A (ja) * 2020-01-31 2023-04-20 オンコデザイン エス．ア． 大環状ｒｉｐ２－キナーゼ阻害剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
UA129504C2 (uk) 2020-05-06 2025-05-14 Ле Лаборатуар Сервьє Нові макроциклічні інгібітори lrrk2-кінази
TW202304935A (zh) 2021-03-18 2023-02-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商Ｈ 朗德貝克公司 富白胺酸重複激酶2（lrrk2）抑制劑
WO2024218285A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Leucine-rich repeat kinase 2 (lrrk2) inhibitors
AR132488A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132487A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013046029A1 (en) * 2011-09-30 2013-04-04 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
WO2013045653A1 (en) * 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
PT1354884E (pt) 2000-12-28 2007-12-24 Ono Pharmaceutical Co Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2006045392A2 (en) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
BR112012006859A2 (pt) 2009-09-29 2019-09-24 Glaxo Group Ltd compostos
AU2011256380C1 (en) * 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013046029A1 (en) * 2011-09-30 2013-04-04 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
WO2013045653A1 (en) * 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516551A (ja) * 2020-01-31 2023-04-20 オンコデザイン エス．ア． 大環状ｒｉｐ２－キナーゼ阻害剤
JP7713461B2 (ja) 2020-01-31 2025-07-25 オンコデザイン プリシジャン メディシン（オーピーエム） 大環状ｒｉｐ２－キナーゼ阻害剤

Also Published As

Publication number Publication date
EP3194405B1 (en) 2018-12-26
WO2016042089A1 (en) 2016-03-24
KR20170048599A (ko) 2017-05-08
TW201625639A (zh) 2016-07-16
PL3194405T3 (pl) 2019-07-31
EA201790626A1 (ru) 2017-07-31
US10377772B2 (en) 2019-08-13
US20170240565A1 (en) 2017-08-24
TR201904514T4 (tr) 2019-04-22
PL3194405T4 (pl) 2019-07-31
SG11201701936WA (en) 2017-04-27
ZA201701841B (en) 2019-08-28
CA2960777A1 (en) 2016-03-24
IL251054A0 (en) 2017-04-30
AU2015316801B2 (en) 2019-03-07
AU2015316801A1 (en) 2017-04-27
HUE043972T2 (hu) 2019-09-30
BR112017005299A2 (pt) 2017-12-12
MX2017003470A (es) 2017-08-07
ES2717510T3 (es) 2019-06-21
CN107108641A (zh) 2017-08-29
DK3194405T3 (en) 2019-04-15
IL251054B (en) 2019-03-31
EP3194405A1 (en) 2017-07-26
EA032838B1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
JP2017529365A (ja) 大環状ｌｒｒｋ２キナーゼ阻害剤
JP6082397B2 (ja) マクロ環状ｌｒｒｋ２キナーゼ阻害剤
JP6046728B2 (ja) 大環状ｆｌｔ３キナーゼ阻害剤
JP5766820B2 (ja) Ｐｉ３キナーゼ阻害剤としての複素環化合物
JP2016510793A (ja) 大環状ｌｒｒｋ２キナーゼ阻害剤
EP4233869A2 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
JP6437140B2 (ja) ピロロピリミジン化合物による抗腫瘍効果増強剤
BR122019020716B1 (pt) heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
WO2015191677A1 (en) Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
JP2016510797A (ja) 大環状塩誘導性キナーゼ阻害剤
WO2018097234A1 (ja) 新規オキソイソキノリン誘導体
JP2016510796A (ja) 大環状ｒｉｐ２キナーゼ阻害剤
CN119487018A (zh) 作为irak 4的配体导向降解剂的杂芳基化合物
CN105732637A (zh) 杂芳化合物及其在药物中的应用
CN111051304A (zh) 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉衍生物
JP6736545B2 (ja) 大環状ｒｉｐ２キナーゼ阻害剤
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
HK40098131A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HK1240586A1 (zh) 大环lrrk2激酶抑制剂
HK1241863B (en) Heterocyclylamines as pi3k inhibitors
HK40027828A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200109